Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

2

By Jacob Gronholt-Pedersen COPENHAGEN, Nov 4 (Reuters) – Novo Nordisk's Wegovy pill beat third-quarter sales forecasts on Wednesday, a test of whether the Danish drugmaker's new oral weight-loss drug

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)